EMEA-002146-PIP01-17

Key facts

Invented name
Ibrance
Active substance
palbociclib
Therapeutic area
Oncology
Decision number
P/0209/2018
PIP number
EMEA-002146-PIP01-17
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of Ewing sarcoma
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Limited

E-mail: pip_enquiries@pfizer.com
Tel. +44 (0)1304 646607

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating